Rationale of the methodological approach to the creation of combined drugs
DOI:
https://doi.org/10.24959/uekj.17.4Keywords:
methodological approach, combination drugs, the creation of the medicines, drug design, algorithmAbstract
Efficient development of new drugs is only possible with a reasonable design research, because it requires integrating and coordinating the efforts of specialists in different fields. Currently there is a huge package of documents, and manuals in the field of registration and production of medicines (drugs). However, there are no generally accepted scientific guidelines about primary research at the pharmaceutical development of combination drugs. Our proposed methodological approach to the primary (basic) investigations and developed on the basis of his scheme (algorithm) of design combination drugs with the well-known active pharmaceutical ingredients (APIs) allows to Optimize research and reduce the risk of a negative result at the final stages of development of the drug.
Aim. To develop model for the initial design fixed-dose combination with known API and develop methodological approach to the creation of combined drugs.
Results. The general scheme (algorithm) was developed for combined drugs based on the combination of well-known API.
Conclusions. Offered methodological approach to designing a fixed combination of active substances, as part of the process of creating combined medicines.
References
Настанова 42-4.3:2011. – Лікарські засоби. Фармацевтична система якості (ICH Q10) / М. Ляпунов, О. Безугла, О. Соловйов та ін. – К.: МОЗ України, 2011. – 22 с.
Настанова СТ-НМОЗУ 42-3.0:2011. – Лікарські засоби. Фармацевтична розробка (ICH Q8) / М. Ляпунов, О. Безугла, Ю. Підпружников та ін. – К.: МОЗ України, 2011. – 33 с.
Подпружников, Ю. В. Хрестоматия фармацевтического качества / Ю. В. Подпружников, А. А. Ишмухаметов, А. С. Немченко и др. – М.: ООО «Группа Ремедиум», 2015. – 432 с.
Challenge and Opportunity on the Critical Path to New Medical Products, FDA, Mach 2004.– Р. 31.
EMEA/CHMP/SWP/258498/2005 Guideline on the non-clinical development of fixed combinations of Medicinal products, London: EMEA, 2005. – Р. 5.
Drug Design & Manufacturing using Product Life cycle Management – HCL Technologies, 2011. – Р. 18.
Taking a Commercial Approach To Drug Development: Business, News & Politics. [Электронный ресурс]. – Режим доступу: http://www.slideshare.net/tmarten/taking-a-commercial-approach-to-drug-development
Yun, Bai. Strategies to Mitigate Technology Transfer and Clinical Manufacturing Risks: Downstream Purification Case Studies: [Электронный ресурс] / Yun Bai. – BioProcess International, 2014. – Режим доступу: http://www.bioprocessintl.com/business/risk-management/strategies-to-mitigate-technology-transfer-and-clinical-manufacturing-risks/
Downloads
Published
Issue
Section
License
Copyright (c) 2017 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
